title: Characteristics of patients with liver disease intravenously exposed to diethylene glycol in China 2006.
abstract: BACKGROUND
  Diethylene glycol (DEG) poisoning is life-threatening. The clinical characteristics of patients with liver disease exposed to intravenous DEG have not been clarified.
  
  
  METHODS
  Sixty-four patients with moderate to severe liver disease exposed to DEG in China in 2006 were investigated.
  
  
  RESULTS
  The daily exposure total dose was 3-6 mL of a 30% (v/v) mixture. Acute renal failure (ARF), the predominant clinical manifestation, occurred in 23.4% (15/64) of these patients. The average time to onset was 6.53 +/- 3.48 days after exposure to DEG. ARF could be differentiated from the hepatorenal syndrome that usually occurs in patients with severe liver disease. The occurrence of ARF was significantly related to pre-existing renal function abnormality, and was not influenced by the allele distribution of DEG-metabolizing enzyme. The liver function profiles did not significantly change after DEG exposure.
  
  
  CONCLUSIONS
  ARF was the main clinical manifestation in this intravenous DEG poisoning accident. The influence of underlying liver disease on DEG poisoning or that of DEG exposure on liver disease has many implications.
authors.affiliation: Hospital for Liver Disease, Sun Yat-Sen University, Guangzhou, China.
authors.forename: Xiao M
authors.initials: XM
authors.lastname: Peng
authors.forename: Ming Xing
authors.initials: MX
authors.lastname: Huang
authors.forename: Lin
authors.initials: L
authors.lastname: Gu
authors.forename: Bing Liang
authors.initials: BL
authors.lastname: Lin
authors.forename: Gui Hua
authors.initials: GH
authors.lastname: Chen
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000328:Adult; D001578:Benzopyrans / Q000008:administration & dosage*; D016022:Case-Control Studies; D002681:China; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D004339:Drug Compounding; D004340:Drug Contamination; D005026:Ethylene Glycols / Q000008:administration & dosage / Q000506:poisoning*; D005260:Female; D006530:Hepatorenal Syndrome / Q000209:etiology; D006801:Humans; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D001578:Benzopyrans; D002756:Cholagogues and Choleretics; D005026:Ethylene Glycols; C013484:diethylene glycol; C023435:armillarisin A